Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis.
Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis.
复制标题
DOI：
10.1093/braincomms/fcab297
复制
发表时间：
2022
影响因子：
4.8
通讯作者：
Rooney AG
中科院分区：
文献类型：
--
作者：
Badenoch JB;Rengasamy ER;Watson C;Jansen K;Chakraborty S;Sundaram RD;Hafeez D;Burchill E;Saini A;Thomas L;Cross B;Hunt CK;Conti I;Ralovska S;Hussain Z;Butler M;Pollak TA;Koychev I;Michael BD;Holling H;Nicholson TR;Rogers JP;Rooney AG
COVID-19后持续神经精神症状的性质和程度尚未确定。为帮助在疫情恢复阶段为心理健康服务规划提供信息，我们系统地确定了COVID-19幸存者的神经精神症状患病率。对于这项预先注册的系统性综述和荟萃分析（PROSPERO ID CRD 42021239750），我们检索了MEDLINE、EMBASE、CINAHL和PsycINFO，截至2021年2月20日，以及我们自己的策展数据库。我们纳入了同行评议的研究，这些研究报告了COVID-19感染后急性期后或更晚时间点的神经精神症状，并在可用的情况下纳入了对照组。对于每项研究，至少有两名作者提取总结数据。对于每种症状，我们使用广义线性混合模型计算了合并患病率。用I2测量杂原子数。对COVID-19住院、严重程度和随访持续时间进行了亚组分析。从2844个唯一标题中，我们纳入了51项研究（n = 18917例患者）。COVID-19后的平均随访时间为77天（范围14-182天）。研究质量通常为中等。最常见的神经精神症状是睡眠障碍[合并患病率= 27.4%（95%置信区间21.4-34.4%）]，其次是疲劳[24.4%（17.5-32.9%）]、客观认知障碍[20.2%（10.3-35.7%）]、焦虑[19.1%（13.3-26.8%）]和创伤后应激[15.7%（9.9-24.1%）]。只有两项研究报告了对照组的症状，这两项研究都报告了COVID-19幸存者比对照组更高的频率。研究间异质性较高（I2 = 79.6-98.6%）。基于住院状态、严重程度或随访持续时间，几乎没有或没有证据表明不同症状的患病率。神经精神症状在COVID-19康复后很常见且持续存在。关于长期后果的文献仍在完善中，但表明在感染后的头6个月，失眠、疲劳、认知障碍和焦虑症的患病率特别高。Badenoch等人在一项系统性综述和荟萃分析中报告了COVID-19后持续长达6个月的频繁神经精神症状，包括失眠、疲劳、焦虑、创伤后症状、认知障碍和情绪障碍。卫生服务部门应针对COVID-19之后对多学科服务（包括神经、神经精神和心理管理）的高需求进行规划。
The nature and extent of persistent neuropsychiatric symptoms after COVID-19 are not established. To help inform mental health service planning in the pandemic recovery phase, we systematically determined the prevalence of neuropsychiatric symptoms in survivors of COVID-19. For this pre-registered systematic review and meta-analysis (PROSPERO ID CRD42021239750), we searched MEDLINE, EMBASE, CINAHL and PsycINFO to 20 February 2021, plus our own curated database. We included peer-reviewed studies reporting neuropsychiatric symptoms at post-acute or later time-points after COVID-19 infection and in control groups where available. For each study, a minimum of two authors extracted summary data. For each symptom, we calculated a pooled prevalence using generalized linear mixed models. Heterogeneity was measured with I2. Subgroup analyses were conducted for COVID-19 hospitalization, severity and duration of follow-up. From 2844 unique titles, we included 51 studies (n = 18 917 patients). The mean duration of follow-up after COVID-19 was 77 days (range 14–182 days). Study quality was most commonly moderate. The most prevalent neuropsychiatric symptom was sleep disturbance [pooled prevalence = 27.4% (95% confidence interval 21.4–34.4%)], followed by fatigue [24.4% (17.5–32.9%)], objective cognitive impairment [20.2% (10.3–35.7%)], anxiety [19.1% (13.3–26.8%)] and post-traumatic stress [15.7% (9.9–24.1%)]. Only two studies reported symptoms in control groups, both reporting higher frequencies in COVID-19 survivors versus controls. Between-study heterogeneity was high (I2 = 79.6–98.6%). There was little or no evidence of differential symptom prevalence based on hospitalization status, severity or follow-up duration. Neuropsychiatric symptoms are common and persistent after recovery from COVID-19. The literature on longer-term consequences is still maturing but indicates a particularly high prevalence of insomnia, fatigue, cognitive impairment and anxiety disorders in the first 6 months after infection. In a systematic review and meta-analysis, Badenoch et al. report frequent neuropsychiatric symptoms persisting up to 6 months after COVID-19, including insomnia, fatigue, anxiety, post-traumatic symptoms, cognitive impairment and mood disorder. Health services should plan for a high requirement for multidisciplinary services (including neurological, neuropsychiatric and psychological management) after COVID-19.
登录
查看更多内容
影响因子：
3.3
作者：
Ferrucci R;Dini M;Groppo E;Rosci C;Reitano MR;Bai F;Poletti B;Brugnera A;Silani V;D'Arminio Monforte A;Priori A
通讯作者：
Priori A
DOI：
10.1016/s2213-2600(21)00383-0
发表时间：
2021-11
期刊：
The Lancet. Respiratory medicine
影响因子：
--
作者：
Evans RA;McAuley H;Harrison EM;Shikotra A;Singapuri A;Sereno M;Elneima O;Docherty AB;Lone NI;Leavy OC;Daines L;Baillie JK;Brown JS;Chalder T;De Soyza A;Diar Bakerly N;Easom N;Geddes JR;Greening NJ;Hart N;Heaney LG;Heller S;Howard L;Hurst JR;Jacob J;Jenkins RG;Jolley C;Kerr S;Kon OM;Lewis K;Lord JM;McCann GP;Neubauer S;Openshaw PJM;Parekh D;Pfeffer P;Rahman NM;Raman B;Richardson M;Rowland M;Semple MG;Shah AM;Singh SJ;Sheikh A;Thomas D;Toshner M;Chalmers JD;Ho LP;Horsley A;Marks M;Poinasamy K;Wain LV;Brightling CE;PHOSP-COVID Collaborative Group
通讯作者：
PHOSP-COVID Collaborative Group
影响因子：
13.8
作者：
Bellan M;Soddu D;Balbo PE;Baricich A;Zeppegno P;Avanzi GC;Baldon G;Bartolomei G;Battaglia M;Battistini S;Binda V;Borg M;Cantaluppi V;Castello LM;Clivati E;Cisari C;Costanzo M;Croce A;Cuneo D;De Benedittis C;De Vecchi S;Feggi A;Gai M;Gambaro E;Gattoni E;Gramaglia C;Grisafi L;Guerriero C;Hayden E;Jona A;Invernizzi M;Lorenzini L;Loreti L;Martelli M;Marzullo P;Matino E;Panero A;Parachini E;Patrucco F;Patti G;Pirovano A;Prosperini P;Quaglino R;Rigamonti C;Sainaghi PP;Vecchi C;Zecca E;Pirisi M
通讯作者：
Pirisi M
影响因子：
7.2
作者：
Afshar Y;Gaw SL;Flaherman VJ;Chambers BD;Krakow D;Berghella V;Shamshirsaz AA;Boatin AA;Aldrovandi G;Greiner A;Riley L;Boscardin WJ;Jamieson DJ;Jacoby VL;Pregnancy CoRonavIrus Outcomes RegIsTrY (PRIORITY) Study
通讯作者：
Pregnancy CoRonavIrus Outcomes RegIsTrY (PRIORITY) Study
影响因子：
3.7
作者：
De Lorenzo R;Conte C;Lanzani C;Benedetti F;Roveri L;Mazza MG;Brioni E;Giacalone G;Canti V;Sofia V;D'Amico M;Di Napoli D;Ambrosio A;Scarpellini P;Castagna A;Landoni G;Zangrillo A;Bosi E;Tresoldi M;Ciceri F;Rovere-Querini P
通讯作者：
Rovere-Querini P